Sector Expert: Michael G. King, Jr.

JMP Securities

Image: Michael G. King, Jr.

Michael G. King Jr. is a managing director and senior biotechnology analyst at JMP Securities. King comes to JMP from Rodman & Renshaw LLC, where he was managing director and senior biotechnology analyst. He has more than 17 years of experience as a leading biotechnology equity research analyst, consistently ranking at the top of Institutional Investor magazine's annual sellside research survey, in addition to being named that publication's "Home Run Hitter" in 2000. King also served as senior vice president of corporate development and communication at ZIOPHARM Oncology (ZIOP:NASDAQ). Prior to joining ZIOPHARM, King was a managing director and senior biotechnology analyst at Wedbush Securities. He holds a bachelor's degree in finance from Baruch College.

Subscribe to
Streetwise Reports

Companies Commented On

  • Abeona Therapeutics Inc.
  • Actinium Pharmaceuticals Inc.
  • ArQule Inc.
  • Asterias Biotherapeutics Inc.
  • BioSpecifics Technologies Corp.
  • Blueprint Medicines Corp.
  • Catalyst Biosciences Inc.
  • Edge Therapeutics Inc.
  • Epizyme Inc.
  • Karyopharm Therapeutics Inc.
  • Loxo Oncology Inc.
  • OncoMed Pharmaceuticals Inc.
  • Pieris Pharmaceuticals Inc.
  • Sorrento Therapeutics Inc.
  • Stemline Therapeutics Inc.
  • Syndax Pharmaceuticals Inc.
  • Synergy Pharmaceuticals Inc.
  • Syros Pharmaceuticals
  • Threshold Pharmaceuticals Inc.
  • WAVE Life Sciences Ltd.


Recent Interviews

2017 Small-Cap Biotech Watchlist Update: Holding Steady in a Volatile Market (4/19/17)
2017_watchlist

The Small-Cap Biotech Watchlist, composed of 20 companies targeting a range of indications including blood cancers and solid tumors, irritable bowel disease and orphan diseases, has posted a modest gain since the first of the year.

2017 Small-Cap Biotech Watchlist: Takeaways for Investors (1/18/17)
2017_watchlist

Why should investors keep an eye on these twenty small-cap biotechs in 2017? The analysts who made the selections for The Life Sciences Report's 2017 Small-Cap Biotech Watchlist laid out their rationales at the Watchlist's launch at the Biotech Showcase in San Francisco on Jan. 11.

19 Companies Selected for the 2017 Small-Cap Biotech Watchlist (1/3/17)
2017_watchlist

Now in its fifth year, the 2017 Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field, and will be presented at the Biotech Showcase in San Francisco in January.

Recent Quotes

"ASTX's shares still sell well below where we believe they could trade."

— Michael G. King, Jr., JMP Securities (9/16/13)
more >

"We are reiterating our Market Outperform rating on ASTX."

— Michael G. King, Jr., JMP Securities (8/19/13)
more >

"We maintain our Market Outperform rating on CYCC."

— Michael G. King, Jr., JMP Securities (8/14/13)
more >

"We maintain our Market Outperform rating on CYCC."

— Michael G. King, Jr., JMP Securities (8/14/13)
more >

"We continue to view ASTX as a highly attractive mid-cap play in the biotech space."

— Michael G. King, Jr., JMP Securities (8/1/13)
more >

"We maintain our Outperform rating for ASTX."

— Michael G. King, Jr., JMP Securities (7/8/13)
more >

"We are initiating coverage on CYCC with a Market Outperform rating."

— Michael G. King, Jr., JMP Securities (7/2/13)
more >

"We reiterate our Market Outperform rating on ASTX."

— Michael G. King, Jr., JMP Securities (4/30/13)
more >



Due to permission requirements, not all quotes are shown.